For reference: 15 mg · ten weeks · injection-site erythema.
I understand the observation; what I do not understand is the mechanism behind it.
I have read the two review articles that come up first and both assert this without a citation to a primary source.
What is actually going on here, physically?
ten weeks at 15 mg is 70 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 15 mg back by 70 days. Whether that reduces injection-site erythema depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 15 mg is 15 mg on day 1 and on day 70. A symptom driven by the rate of change has 70 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot injection-site erythema against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
More usefully, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Four half-lives between steps, minimum. Work it out for your agent.
edited 23 Sept 2025 by esther_vandeVelde — tightened the wording; no substantive change
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMore usefully, escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Worth being precise here: titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Stepping back is a normal adjustment, not a failure.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Slower costs time and nothing else. The ceiling is the same.
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Hold rather than escalate while symptoms are active. Always.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
The top of the schedule is not the target. The working dose is.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.